CARDIAC INVOLVEMENT IN POMPE DISEASE: FROM PATHOPHYSIOLOGY TO MULTIMODALITY CARDIOVASCULAR ASSESSMENT AND THERAPEUTIC PERSPECTIVES

Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is a rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GAA gene encoding lysosomal acid α-glucosidase. Deficient enzyme activity results in progressive intralysosomal glycogen accumulation, particularly in skeletal, respiratory, and, in the classic infantile phenotype, cardiac muscle. Cardiac involvement is most prominent in classic infantile-onset Pompe disease, in which severe myocardial hypertrophy, ventricular remodeling, diastolic dysfunction, and electrical abnormalities may develop early in life. In contrast, clinically significant cardiac disease is uncommon in late-onset Pompe disease, although subtle abnormalities have occasionally been identified using sensitive cardiovascular imaging techniques. Cardiovascular assessment therefore needs to be adapted to the clinical phenotype and age of onset. Electrocardiography and echocardiography remain the principal first-line investigations, whereas speckle-tracking echocardiography and cardiac magnetic resonance may provide complementary information in selected patients. Cardiac magnetic resonance allows accurate assessment of ventricular volumes and mass and provides tissue characterization, although current evidence remains limited and heterogeneous. Enzyme replacement therapy has substantially changed the natural history of classic infantile Pompe disease, with regression of myocardial hypertrophy and improvement in cardiac function when treatment is initiated early. The cardiovascular response in late-onset disease appears considerably less pronounced. This review summarizes the mechanisms of cardiac involvement in Pompe disease, its clinical and electrocardiographic manifestations, the contribution of multimodality cardiovascular imaging, practical diagnostic considerations for cardiologists, and current and emerging therapeutic perspectives. Particular emphasis is placed on the role of the cardiologist in recognizing atypical cardiac phenotypes and participating in multidisciplinary long-term management.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-01
DOI
https://doi.org/10.5281/zenodo.23849832
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CARDIAC INVOLVEMENT IN POMPE DISEASE: FROM PATHOPHYSIOLOGY TO MULTIMODALITY CARDIOVASCULAR ASSESSMENT AND THERAPEUTIC PERSPECTIVES

N. Annane² Z. Bennoui*¹
1 links
Zenodo (CERN European Organization for Nuclear Research)
Lysosomal Storage Disorders Research
article

CARDIAC INVOLVEMENT IN POMPE DISEASE: FROM PATHOPHYSIOLOGY TO MULTIMODALITY CARDIOVASCULAR ASSESSMENT AND THERAPEUTIC PERSPECTIVES

N. Annane² Z. Bennoui*¹
article en

Abstract

Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is a rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GAA gene encoding lysosomal acid α-glucosidase. Deficient enzyme activity results in progressive intralysosomal glycogen accumulation, particularly in skeletal, respiratory, and, in the classic infantile phenotype, cardiac muscle. Cardiac involvement is most prominent in classic infantile-onset Pompe disease, in which severe myocardial hypertrophy, ventricular remodeling, diastolic dysfunction, and electrical abnormalities may develop early in life. In contrast, clinically significant cardiac disease is uncommon in late-onset Pompe disease, although subtle abnormalities have occasionally been identified using sensitive cardiovascular imaging techniques. Cardiovascular assessment therefore needs to be adapted to the clinical phenotype and age of onset. Electrocardiography and echocardiography remain the principal first-line investigations, whereas speckle-tracking echocardiography and cardiac magnetic resonance may provide complementary information in selected patients. Cardiac magnetic resonance allows accurate assessment of ventricular volumes and mass and provides tissue characterization, although current evidence remains limited and heterogeneous. Enzyme replacement therapy has substantially changed the natural history of classic infantile Pompe disease, with regression of myocardial hypertrophy and improvement in cardiac function when treatment is initiated early. The cardiovascular response in late-onset disease appears considerably less pronounced. This review summarizes the mechanisms of cardiac involvement in Pompe disease, its clinical and electrocardiographic manifestations, the contribution of multimodality cardiovascular imaging, practical diagnostic considerations for cardiologists, and current and emerging therapeutic perspectives. Particular emphasis is placed on the role of the cardiologist in recognizing atypical cardiac phenotypes and participating in multidisciplinary long-term management.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 13%
Lysosomal Storage Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon